BIM
ALNY icon

Bridges Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bridges Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,216
Closed -$484K – 395
2025
Q4 		$484K Buy
1,216
+422
+53% +$187K 0.01% 299
2025
Q3 		$362K Buy
+794
New +$323K ﹤0.01% 329

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bridges Investment Management's ALNY Position: Q1 2026 in Review

Bridges Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,216 shares — an estimated $484K sold.

Bridges Investment Management first reported a position in ALNY in Q3 2025 and held it in 2 quarters. The position peaked at $484K in Q4 2025. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Bridges Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bridges Investment Management sold 1,216 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $484K.
  • Bridges Investment Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Bridges Investment Management's Alnylam Pharmaceuticals position peaked at $484K in Q4 2025.
  • 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Bridges Investment Management's 13F filing for Q1 2026, filed 4 May 2026.